



# SEMINARIO

**Mark Mercola, Ph.D.**

*Professor*

*Stanford Cardiovascular Institute*

*Department of Medicine, Stanford University*

**“Generating Safe and Effective Drugs for Heart Disease and Cancer using Patient iPSCs”**

Aula Magna – Clinica Pediatrica

Viale Regina Elena 324 - Roma

**Martedì 12 Novembre, ore 12.00**

Prof. Mercola's research has focused on the identification of many of the factors that are responsible for inducing and forming the heart during embryonic development. His work has provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from embryonic and pluripotent stem cells. He has been a pioneer in the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology, and drug development. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. His academic research is focused on developing and using quantitative assays of patient-specific iPSC-cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and to screen for cardiovascular toxicities associated with anti-cancer tyrosine kinase inhibitor treatments.

*Hosted by: Elisa Messina (elisa.messina@uniroma1.it) and Roberto Gaetani (roberto.gaetani@uniroma1.it)*